Factor XIa Tied to Benefit Beyond Stroke Prevention

by | May 8, 2026 | Health

Spread the love
Results from the OCEANIC-STROKE trial show that the investigational Factor XIa inhibitor, asundexian, not only reduces the recurrent ischaemic stroke risk, but when they do occur, they are less likely to be disabling or fatal.
Medscape Medical News

Written By

Written by Albert Pham, News Curator and Blogger

Related Posts

0 Comments